{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:14:09Z","timestamp":1768882449329,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12185-025-04062-5","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T15:37:45Z","timestamp":1757691465000},"page":"81-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Area under tacrolimus concentrations predict outcomes after unrelated allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2875-3980","authenticated-orcid":false,"given":"Susumu","family":"Tanoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Ouchi-Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Hosoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saya","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaichi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"4062_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/leu.2016.288","volume":"31","author":"J Kanda","year":"2017","unstructured":"Kanda J, Morishima Y, Terakura S, Wake A, Uchida N, Murata M, et al. Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation. Leukemia. 2017;31:663\u20138.","journal-title":"Leukemia"},{"key":"4062_CR2","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1158\/1078-0432.CCR-20-4856","volume":"27","author":"T Konuma","year":"2021","unstructured":"Konuma T, Kanda J, Kuwatsuka Y, Yanada M, Kondo T, Kimura F, et al. Differential effect of graft-versus-host disease on survival in acute leukemia according to donor type. Clin Cancer Res. 2021;27:4825\u201335.","journal-title":"Clin Cancer Res"},{"key":"4062_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.leu.2403343","volume":"18","author":"Y Kanda","year":"2004","unstructured":"Kanda Y, Izutsu K, Hirai H, Sakamaki H, Iseki T, Kawa K, et al. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia. 2004;18:1013\u20139.","journal-title":"Leukemia"},{"key":"4062_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/sj.bmt.1703097","volume":"28","author":"A Hiraoka","year":"2001","unstructured":"Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Masaoka T, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;28:181\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"4062_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbmt.2009.08.010","volume":"16","author":"F Malard","year":"2010","unstructured":"Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Mohty M, et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16:28\u201334.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4062_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbmt.2011.08.016","volume":"18","author":"R Ram","year":"2012","unstructured":"Ram R, Storer B, Mielcarek M, Sandmaier BM, Maloney DG, Storb R, et al. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:414\u201322.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4062_CR7","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Thomas ED, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"4062_CR8","first-page":"250","volume":"28","author":"KM Sullivan","year":"1991","unstructured":"Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Loughran T, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250\u20139.","journal-title":"Semin Hematol"},{"key":"4062_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Sandmaier B, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4062_CR10","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Saber W, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123:3664\u201371.","journal-title":"Blood"},{"key":"4062_CR11","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Storer B, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"issue":"3","key":"4062_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"4062_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/ajh.20710","volume":"81","author":"Y Kanda","year":"2006","unstructured":"Kanda Y, Hyo R, Yamashita T, Fujimaki K, Oshima K, Sakamaki H, et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol. 2006;81:838\u201344.","journal-title":"Am J Hematol"},{"key":"4062_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/sj.bmt.1704374","volume":"33","author":"N Ogawa","year":"2004","unstructured":"Ogawa N, Kanda Y, Matsubara M, Asano Y, Nakagawa M, Hirai H, et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplant. 2004;33:549\u201352.","journal-title":"Bone Marrow Transplant"},{"key":"4062_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbmt.2011.06.008","volume":"18","author":"T Mori","year":"2012","unstructured":"Mori T, Kato J, Shimizu T, Aisa Y, Nakazato T, Okamoto S, et al. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors. Biol Blood Marrow Transplant. 2012;18:229\u201334.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4062_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41409-018-0267-5","volume":"54","author":"PA Hagen","year":"2019","unstructured":"Hagen PA, Adams W, Smith S, Tsai S, Stiff P. Low mean post-transplantation tacrolimus levels in weeks 2\u20133 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Bone Marrow Transplant. 2019;54:155\u20138.","journal-title":"Bone Marrow Transplant"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04062-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04062-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04062-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:03:22Z","timestamp":1768835002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04062-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4062"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04062-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H. Yokoyama reports research funding from Shionogi Pharmaceuticals outside the submitted work; K. Nishiwaki reports research funding from Alexion Pharmaceuticals, personal fees from Alexion Pharmaceuticals, Argenx Japan K.K. and Pfizer Japan outside the submitted work; N. Dobashi reports personal fees from Otsuka Pharmaceuticals outside the submitted work; S. Yano reports research funding from Otsuka Pharmaceuticals, Lilly Pharma and Fuji pharmaceuticals, personal fees from Astra Zeneca K.K. and Daiichi Sankyo outside the submitted work;.the other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}